Abstract:LINC00092 is poorly expressed in Thyroid cancer (TC), while its role in TC
tumorigenesis is still elusive. This study aimed to reveal the role and
regulatory mechanism of LINC00092 in TC.RNA immunoprecipitation and dual luciferase reporter assays were employed to
ascertain the relationships among lipoma preferred partner (LPP), miR-542-3p,
and LINC00092. qRT-PCR analysis was performed to detect their expression levels
in TC. LPP protein productions were evaluated via western blotting. CCK-8,
transwell, and colony formation assays were done to estimate TC cells’
biological functions. A murine xenograft model was built to observe tumor
formation in vivo.LINC00092 overexpression decreased the expression levels of miR-542-3p, and LPP
was targeted by miR-542-3p. In TC cells and tissues, the elevation of
miR-542-3p, and low amounts of LINC00092 and LPP can be observed. Both LINC00092
and SPAG6 were considered as the antineoplastic factors in TC since their
overexpression dramatically repressed TC cells’ invasive and
proliferative potentials, while miR-542-3p exerted the opposite functions in TC.
The ectopic expression of LINC00092 also suppressed tumor growth in vivo. In
addition, it revealed that miR-542-3p upregulation reversed LINC00092
overexpression-mediated effects on TC cells. At the same time, the enhanced
influences of TC cells caused by miR-542-3p upregulation could be attenuated by
the enforced LPP.This study innovatively reveals that LINC00092 acts as an antineoplastic lncRNA
to restrain the development of TC via regulating miR-542-3p/LPP. The
findings of this study may provide a prospective drug target on
LINC00092/miR-542-3p/LPP axis for the treatment of TC.